<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166673</url>
  </required_header>
  <id_info>
    <org_study_id>DirecNet 006</org_study_id>
    <secondary_id>HD041890</secondary_id>
    <secondary_id>HD041919</secondary_id>
    <secondary_id>HD041908</secondary_id>
    <secondary_id>HD041906</secondary_id>
    <secondary_id>HD041918</secondary_id>
    <secondary_id>HD041915</secondary_id>
    <nct_id>NCT00166673</nct_id>
  </id_info>
  <brief_title>Pilot Study of the Navigator Continuous Glucose Monitor</brief_title>
  <official_title>A Pilot Study to Evaluate the Navigator Continuous Glucose Sensor in the Management of Type 1 Diabetes in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <brief_summary>
    <textblock>
      This study is being done to find out how accurate the Navigator continuous glucose monitor is&#xD;
      in children. It is also being done to see if use of the Navigator can improve blood sugar&#xD;
      control and help prevent low blood sugar events. This study has three basic parts: Use of the&#xD;
      Navigator at home for one week without being able to see the blood sugar readings; a Baseline&#xD;
      visit or a 24-hour admission to a research unit of the hospital to find out how well the&#xD;
      Navigator measures the blood sugar; and then 3 months use of the Navigator at home as an aid&#xD;
      to diabetes care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 60 children will be recruited from five centers in the United States to&#xD;
      participate in this study. The information gained from this study will be used to plan a&#xD;
      larger study in which half of the patients will use the Navigator and half will not. Children&#xD;
      who participate in this study will not be eligible to take part in the larger study.&#xD;
&#xD;
      The Navigator provides a glucose reading every 60 seconds (or 1440 readings a day). Each&#xD;
      sensor is designed to provide readings for up to 120 hours. It has alarms for hypoglycemia&#xD;
      and hyperglycemia and for projected high and low glucose values. The alarm set points can be&#xD;
      adjusted by the user. The Navigator also has a trend arrow indicating the glucose rate of&#xD;
      change (&gt;-2 mg/dL/min, -2 to -1 mg/dL/min, -1 to 1 mg/dL/min, 1 to 2 mg/dl/min, and &gt;2&#xD;
      mg/dl/min). Subjects can enter events, such as when they took insulin, ate, or exercised. The&#xD;
      sensor requires calibration values to be entered 3 times during the first day of wear at&#xD;
      1-hour, 3-hours, and 24-hours and does not require additional calibration values. The values&#xD;
      are entered directly into the Navigator which has a TheraSense Freestyle home glucose meter&#xD;
      built into the unit. The Navigator has not yet been approved by the FDA. The Navigator&#xD;
      currently under review by the FDA will limit sensor wear to 3 days.&#xD;
&#xD;
      Beginning the Study&#xD;
&#xD;
      When a child enters the study, the following will be done:&#xD;
&#xD;
        1. Questionnaires will be completed.&#xD;
&#xD;
             -  Parents and children (if at least 9 years old) will be asked to fill out&#xD;
                questionnaires on a computer in the clinic. The questions will be about the child's&#xD;
                diabetes, how the diabetes is being treated, and how the diabetes affects the&#xD;
                parent and child.&#xD;
&#xD;
             -  Children who are using insulin pump therapy and are at least 9 years old and&#xD;
                parents will be interviewed about the child's diabetes management habits at home.&#xD;
                The interview will be conducted by phone by trained interviewers who are at Nemours&#xD;
                Children's Clinic in Jacksonville, Florida, one of the study sites.&#xD;
&#xD;
        2. Blood will be drawn to measure glycosylated hemoglobin (HbA1c).&#xD;
&#xD;
        3. Parents and children will be instructed on using the Navigator. The first sensor will be&#xD;
           inserted by the parent or child with guidance from the study nurse. During the first&#xD;
           week, the parent and child will not be able to see the results from the Navigator.&#xD;
&#xD;
        4. Children will be asked to do the following before returning for the Baseline Visit or&#xD;
           the hospital stay about 1 week later:&#xD;
&#xD;
             -  Check the blood sugar using the Freestyle meter built into the Navigator at least 4&#xD;
                times a day&#xD;
&#xD;
             -  Wear the Navigator sensor everyday and change the sensor at the end of day 5&#xD;
&#xD;
             -  On the day a new sensor is started, do 3 fingerstick blood sugar readings using the&#xD;
                built-in Freestyle meter to calibrate the Navigator&#xD;
&#xD;
             -  Enter a meal marker event into the Navigator each time your child has a meal or&#xD;
                snack&#xD;
&#xD;
             -  Insert a new sensor 1, 2, 3, or 4 days before your child will stay in the hospital&#xD;
&#xD;
             -  Bring any used sensors, including the packaging and inserting device to the&#xD;
                Baseline Visit or hospital stay&#xD;
&#xD;
      Baseline Visit Children who are using Lantus with MDI therapy will return for a Baseline&#xD;
      Visit approximately one week (7-12 days) after the enrollment visit.&#xD;
&#xD;
      Hospital Stay Those children who are using insulin pump therapy will return for a hospital&#xD;
      stay approximately one week (7-12 days) after the enrollment visit and will use the Navigator&#xD;
      for about 24 hours. The last sensor that was placed at home will continue to be worn during&#xD;
      the hospital stay. A new sensor will also be placed so that your child has 2 sensors inserted&#xD;
      during the hospital stay to see how closely the 2 sensors agree.&#xD;
&#xD;
      A CGMS sensor will be inserted and calibrated one hour later.&#xD;
&#xD;
      A small tube called a catheter will be placed in a vein in the child's arm and will stay in&#xD;
      the vein while the child is in the hospital. From this tube, a very small blood sample will&#xD;
      be drawn every 30 minutes during the hospital stay. After breakfast, blood samples will be&#xD;
      taken about every 10 minutes for about an hour. For children who are at least 7 years old,&#xD;
      blood samples will be taken about every 20 minutes during a period of exercise in the&#xD;
      afternoon.&#xD;
&#xD;
      Procedures at Home after the Baseline Visit or Hospital Stay&#xD;
&#xD;
        1. Use the Navigator.&#xD;
&#xD;
             -  The Navigator should be worn all of the time for 3 months.&#xD;
&#xD;
             -  The sensor must be replaced every 5 days.&#xD;
&#xD;
             -  With each sensor wear 4 blood sugar readings must be done using the built-in&#xD;
                Freestyle meter to calibrate the Navigator.&#xD;
&#xD;
             -  Enter a meal marker event into the Navigator each time a meal or snack is eaten.&#xD;
&#xD;
             -  Children may be asked to insert a new sensor 5 days before some of the study visits&#xD;
                to allow the study personnel to look at the skin after the sensor has been worn for&#xD;
                5 days.&#xD;
&#xD;
        2. Download the Navigator - Once a week, children will need to download the glucose results&#xD;
           from the Navigator, which will then be emailed to the study coordinating center.&#xD;
&#xD;
        3. Use Algorithms for Diabetes Management Decisions - The study doctor or nurse will give&#xD;
           the parents and children instructions (Algorithms) for how to make changes to diabetes&#xD;
           management from the results of the Navigator. The instructions will be used by the&#xD;
           parents and children to make decisions as they receive the results from the device.&#xD;
&#xD;
        4. Phone Interviews - After 3 days and 2, 4, 8, and 10 weeks after the children leave the&#xD;
           hospital, one of the staff will call to see how they is doing with the Navigator and the&#xD;
           instructions for diabetes management decisions. We will ask what the child ate in the&#xD;
           last meal before the call. We also will ask if the child has been sick or under any&#xD;
           stress. For females who have started menstruating, we will ask about her menstrual&#xD;
           cycle.&#xD;
&#xD;
      Study Visits&#xD;
&#xD;
      Children will return to the diabetes clinics for visits 1, 3, 7, and 13 weeks after the&#xD;
      hospital stay. At these visits, the following will be done:&#xD;
&#xD;
        1. Any used sensors, including the packaging and inserting device will be collected.&#xD;
&#xD;
        2. The skin will be looked at where the Navigator has been worn.&#xD;
&#xD;
        3. The Navigator and the child's insulin pump will be downloaded and reviewed with the&#xD;
           parent and child.&#xD;
&#xD;
        4. The diabetes management instructions will be reviewed with the parent and child to&#xD;
           determine if the instructions have been helpful or if they need to be changed.&#xD;
&#xD;
      At the 3, 7, and 13- week visits, parents and children (if at least 9 years old) will be&#xD;
      asked to complete a questionnaire about how much you liked or disliked the instructions that&#xD;
      were given for using the results of the Navigator.&#xD;
&#xD;
      At the 7-week visit, the following will also be done in addition to the child's regular&#xD;
      clinic visit:&#xD;
&#xD;
      1. Blood will be drawn to measure the HbA1c.&#xD;
&#xD;
      At the 13-week visit, the following will also be done in addition to the child's regular&#xD;
      clinic visit:&#xD;
&#xD;
        1. Blood will be drawn to measure the HbA1c.&#xD;
&#xD;
        2. Questionnaires will be completed&#xD;
&#xD;
             -  Parents and children (if at least 9 years old) will be asked to complete the same&#xD;
                questionnaires and the phone interview that were done during the first visit.&#xD;
&#xD;
             -  Parents and children will be asked to complete one more questionnaire about how&#xD;
                much they like using the Navigator.&#xD;
&#xD;
        3. If the children are willing to continue using the Navigator, they will be given&#xD;
           additional sensors to use as often as they would like and they will return for another&#xD;
           regular clinic visit in about 3 months (26-week visit). At that visit, the skin will be&#xD;
           looked at where the Navigator was used, the HbA1c will be measured, and the parents and&#xD;
           children will be asked to complete the same questionnaires that were completed at the&#xD;
           13-week visit about how much they liked using the Navigator and the instructions that&#xD;
           were given for using the results of the Navigator.&#xD;
&#xD;
      Those who decide to continue using the Navigator will be seen again at 26-weeks.&#xD;
&#xD;
        -  At the 26-week visit, subjects will be given the choice to continue in the study until&#xD;
           the device is approved by the FDA or until Abbott Diabetes Care can no longer provide&#xD;
           supplies for the study. Subjects who agree to continue in the study will sign an&#xD;
           addendum to the informed consent.&#xD;
&#xD;
        -  Subjects who continue in the study will return to the clinic every 3 months for a&#xD;
           follow-up visit. The same procedures completed during the 26-week visit will be&#xD;
           completed at each subsequent visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of using the Navigator sensor on a daily basis (Average number of sensors used per week, Average number of hours of use per sensor, Number of sensors per week that fail to calibrate)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Navigator Accuracy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychosocial Questionnaires</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory assessment of impact of Navigator on HbA1c</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Diabetes Mellitus, Insulin-Dependent</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FreeStyle Navigator Continuous Glucose Monitoring System</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one&#xD;
             year The diagnosis of type 1 diabetes is based on the investigator's judgment; C&#xD;
             peptide level and antibody determinations are not needed.&#xD;
&#xD;
          -  Age 3.0 years to less than 18.0 years&#xD;
&#xD;
          -  Subject has used a downloadable insulin pump or Lantus with MDI of a short-acting&#xD;
             insulin (e.g. Humalog or Novolog) for at least 6 months&#xD;
&#xD;
          -  Parent/guardian and subject understand the study protocol and agree to comply with it&#xD;
&#xD;
          -  Subjects &gt;9.0 years old and primary care giver (i.e., parent or guardian) comprehend&#xD;
             written English&#xD;
&#xD;
          -  Subject has a home computer with email access&#xD;
&#xD;
          -  For females, subject not intending to become pregnant during the next 3 months&#xD;
&#xD;
          -  No expectation that subject will be moving out of the area of the clinical center&#xD;
             during the next 3 months&#xD;
&#xD;
          -  Informed Consent Form signed by the parent/guardian and Child Assent Form signed by&#xD;
             the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of a significant medical disorder that in the judgment of the&#xD;
             investigator will affect the wearing of the sensors or the completion of any aspect of&#xD;
             the protocol.&#xD;
&#xD;
          -  The presence of any of the following diseases:&#xD;
&#xD;
               -  Asthma if treated with systemic or inhaled corticosteroids in the last 6 months&#xD;
&#xD;
               -  Cystic fibrosis&#xD;
&#xD;
               -  Other major illness that in the judgment of the investigator might interfere with&#xD;
                  the completion of the protocol (Adequately treated thyroid disease and celiac&#xD;
                  disease do not exclude subjects from enrollment)&#xD;
&#xD;
          -  Inpatient psychiatric treatment in the past 6 months for either the subject or the&#xD;
             subject's primary care giver (i.e., parent or guardian).&#xD;
&#xD;
          -  Current use of oral/inhaled glucocorticoids or other medications, which in the&#xD;
             judgment of the investigator would be a contraindication to participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William V Tamborlane, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Pediatric Endocrinology and Diabetes, Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jaeb Center for Health Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, University of Iowa Carver College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Buckingham B, Ruedy K, Kollman C, Beck R, Tamborlane W, Mauras N, Weinzimer S, Chase P, Tsalikian E; and the Diabetes Research in Children Network (DirecNet) Study Group. Family Assessment of the Utility of the DirecNet Applied Treatment Algorithm (DATA) for Insulin Adjustments in Real-Time and Retrospective Analyses of Continuous Glucose Monitoring (CGM) Diabetes 2006; 55(Suppl.1): A453</citation>
  </results_reference>
  <results_reference>
    <citation>Fiallo-Scharer R, Tamborlane W, Buckingham B, Wysocki T, Weinzimer S, Tsalikian E, Beck R, Ruedy K, Kollman C; and the Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Research in Children Network (DirecNet) Pilot Study to Evaluate the FreeStyle NavigatorÂ® Continuous Glucose Monitoring System in the Management of T1D in Children. Diabetes 2006; 55(Suppl.1): A452.</citation>
  </results_reference>
  <results_reference>
    <citation>Wilson DM, Beck RW, Tamborlane WV, Dontchev MJ, Kollman C, Chase P, Fox LA, Ruedy KJ, Tsalikian E, Weinzimer SA; DirecNet Study Group. The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care. 2007 Jan;30(1):59-64.</citation>
    <PMID>17192334</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetes Research in Children Network (DirecNet) Study Group. Relative accuracy of the BD Logic and FreeStyle blood glucose meters. Diabetes Technol Ther. 2007 Apr;9(2):165-8.</citation>
    <PMID>17425442</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetes Research in Children Network (DirecNet) Study Group, Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy KJ, Tansey M, Weinzimer SA, Wysocki T. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007 Oct;151(4):388-93, 393.e1-2. Epub 2007 Aug 24.</citation>
    <PMID>17889075</PMID>
  </results_reference>
  <results_reference>
    <citation>Messer L, Ruedy K, Coffey J, Englert K, Caswell K, Steffen A; and the Diabetes Research in Children Network (DirecNet) Study Group. Pediatric Educators' Role in Successful Continuous Glucose Monitoring. Diabetes 2007; 56(Suppl.1): A617.</citation>
  </results_reference>
  <results_reference>
    <citation>Diabetes Research In Children Network (DirecNet) Study Group, Buckingham B, Xing D, Weinzimer S, Fiallo-Scharer R, Kollman C, Mauras N, Tsalikian E, Tamborlane W, Wysocki T, Ruedy K, Beck R. Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator). Pediatr Diabetes. 2008 Apr;9(2):142-7. doi: 10.1111/j.1399-5448.2007.00301.x. Epub 2008 Jan 24.</citation>
    <PMID>18221427</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Insulin-Dependent</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Continuous Glucose Monitoring Devices</keyword>
  <keyword>Electronic Data Collection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

